<?xml version="1.0" encoding="UTF-8"?>
<p>The cost-effectiveness of HBV screening has been studied in several studies from the hematology-oncology field, where a universal screening strategy was found to be cost-effective in studies with patients having solid tumors and hematologic malignancies before chemotherapy.
 <sup>
  <xref rid="bibr109-1759720X20912646" ref-type="bibr">109</xref>,
  <xref rid="bibr110-1759720X20912646" ref-type="bibr">110</xref>
 </sup> A tool for HBV risk calculation was used in a US cohort with hematologic or solid malignancies,
 <sup>
  <xref rid="bibr111-1759720X20912646" ref-type="bibr">111</xref>
 </sup> and it seemed to improve cost-effectiveness by screening high-risk patients only. We were unable to identify similar studies assessing HBV screening cost-effectiveness in rheumatic patients prior to immunosuppression.
</p>
